The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHRM.L Regulatory News (PHRM)

  • There is currently no data for PHRM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

21 May 2007 07:02

Phorm Inc21 May 2007 Embargoed for release until 7a.m. 21/05/07 Directorate Change Phorm, Inc ("Phorm" or the "Company") Further to the Company's previous announcement on 8th March 2007, the Company(AIM: PHRM and PHRX) is pleased to announce today that David Dorman, ChristopherLawrence and Virasb Vahidi have joined the Board of Phorm, Inc. David Dorman has been an advisor to the Company since July 2006. He is currentlysenior advisor and partner at global private equity firm Warburg Pincus and waspreviously chairman and chief executive officer of AT&T Corp. Before that, hewas CEO of Concert, the global venture created by AT&T and BritishTelecommunications. Mr Dorman serves on the Boards of Motorola, Inc., CVSCorporation, Firethorn Mobile, LLC, and YUM! Brands, Inc. Christopher Lawrence is currently vice chairman of Rothschild, Inc. Prior tojoining Rothschild in 2005, Mr Lawrence was chief strategic officer of CreditSuisse Group as well as a vice chairman of Credit Suisse First Boston. He beganhis investment banking career at Salomon Brothers in 1981. Virasb Vahidi, who is Phorm's chief operating officer, is an internationalbusiness executive with a distinguished career encompassing senior finance,strategy and planning roles in global companies including AT&T Corp. andAmerican Airlines, Inc. Mr Vahidi was most recently senior vice president ofcorporate strategy and development at AT&T, where he was the financial architectof the AT&T Corp/SBC Communications, Inc. merger and co-leader of theintegration team. As also notified on 8th March, David Svendsen, chairman, and Dave Gwozdz havestepped down from the Board of the Company. Dave Gwozdz will remain as US seniorvice president, Business Development and Sales for Phorm. Commenting on the new Board directors, Kent Ertugrul, chairman and CEO of Phorm,said: "We are delighted to welcome Dave, Chris and Virasb to the Board. Theyeach bring complementary skills and experience of an exceptional calibre. Theirwealth of expertise and knowledge will be invaluable as we continue to developour business." "We are grateful to David Svendsen and Dave Gwozdz for their contribution to theBoard and wish them well in the future." Save as set out in the Appendix, there are no further details in relation to theabove appointments which require disclosure under paragraph (g) of Schedule 2 tothe AIM Rules. Ends For EnquiriesPhorm, Inc. +44 870 405 7722Kent Ertugrul (Chairman & Chief Executive) Edelman Financial PR +44 20 7344 1325Paul Lockstone +44 7876 685200 Canaccord Adams Limited +44 20 7050 6500Nominated AdviserMark WilliamsAndrew Chubb Notes to editors Phorm, Inc. was formerly known as 121Media Inc. Appendix Information provided in accordance with paragraph g of Schedule 2 to the AIMrules: (i) the director's full name and age together with any previous names; David Wyatt Dorman, Age 53, None (ii) the names of all companies and partnerships of which the director has beena director or partner at any time in the previous five years, indicating whetheror not the director is still a director or partner; Name of Company Period of DirectorshipAT&T 2002-2006CVS 2006-PresentFirethorn Mobile, LLC 2006-PresentMotorola 2006-PresentSABRE 1999-2002SAIC 1998-2002Scientific Atlanta 1998-2006Yum! Brands 2005-Present (i) the director's full name and age together with any previous names; Christopher Rueckert Lawrence, Age 53, None (ii) the names of all companies and partnerships of which the director has beena director or partner at any time in the previous five years, indicating whetheror not the director is still a director or partner; Name of Company Period of Directorship:120 East End Avenue 1997 (approximately)-Present (i) the director's full name and age together with any previous names; Virasb Vahidi, Age 40, None (ii) the names of all companies and partnerships of which the director has beena director or partner at any time in the previous five years, indicating whetheror not the director is still a director or partner; None This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Apr 201610:00 amRNSUpdate and Resignation of Nominated Adviser
16th Mar 201612:37 pmRNSIssue of US$500,000 of Convertible Loan Notes
16th Mar 20167:00 amRNSIssue of US$500,000 of Convertible Loan Notes
25th Feb 20168:02 amRNSFunding Update and Statement re Suspension
25th Feb 20167:55 amRNSSuspension - Phorm Corporation Limited
4th Feb 20166:05 pmRNSFunding Update
1st Feb 20163:49 pmRNSSubscription Update, New Subscription & Loan
21st Jan 20167:00 amRNSPhorm Awarded TRUSTe Certified Privacy Seal
18th Jan 20167:00 amRNSSubscription & Operational Update
5th Jan 20162:00 pmRNSTR-1: Notification of major interest in shares
23rd Dec 20151:00 pmRNSRevised Non-Executive Director Compensation
22nd Dec 20157:00 amRNSDirectorate Change
7th Dec 20157:00 amRNSRepricing of Options
3rd Dec 201511:00 amRNSPhorm Enables Hover Rate with Insomnis Media
1st Dec 20157:00 amRNSNew Share Option Plan and Grant of Options
18th Nov 20157:00 amRNSTR-1: Notifications of Major Interests in Shares
28th Oct 20157:00 amRNSPartnering Agreement with INSOMNIS Media Limited
20th Oct 20157:00 amRNSAgreement with Causemo, Inc.
13th Oct 20157:00 amRNSPhorm Hires Chief Revenue Officer
9th Oct 20157:00 amRNSAgreement with Boston Globe Media Group
30th Sep 20151:33 pmRNSInterim Results
28th Aug 20152:38 pmRNSResult of AGM
10th Aug 20157:00 amRNSNotice of Annual General Meeting
7th Aug 20157:48 amRNSEquity fundraising of approximately £3.2 million
29th Jul 20157:02 amRNSUpdate re Board Changes
28th Jul 20157:00 amRNSLoan Agreement & Convertible Loan Note Extension
15th Jul 201511:21 amRNSBoard and Management Changes
3rd Jul 20157:00 amRNSOperational Update
2nd Jul 20157:16 amRNSDirectorate Change
30th Jun 20157:00 amRNSAnnual Financial Report
8th May 20154:00 pmRNSTR-1: Notification of major interest in shares
22nd Apr 20157:00 amRNSEquity Fundraising of £6.0 million Gross
21st Apr 20154:22 pmRNSOperational Update
16th Mar 20153:45 pmRNSDirectorate Change
25th Feb 20157:02 amRNSBoard Changes
19th Jan 20157:00 amRNSEquity fundraising of approximately £6.25 million
16th Jan 20157:21 amRNSOperational Update
8th Dec 20147:00 amRNSEquity Fundraising
28th Oct 20147:00 amRNSTR-1: Notification of major interest in shares
8th Oct 20147:00 amRNSEquity fundraising of £4.47 million
6th Oct 20147:00 amRNSOperational Update
22nd Aug 20147:05 amRNSSubscription To Raise £2.4 million
22nd Aug 20147:00 amRNSInterim Results
24th Jul 20142:31 pmRNSResult of Annual General Meeting
27th Jun 20147:30 amRNSGlobal Operations Update
27th Jun 20147:05 amRNSNotice of Annual General Meeting and Board Changes
27th Jun 20147:00 amRNSFinal Results for the Year Ended 31 December 2013
23rd Apr 20144:25 pmRNSTR-1: Notification of major interest in shares
14th Apr 201412:40 pmRNSResult of EGM
27th Mar 20147:00 amRNSProposed £10m Placing & Notice of EGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.